Day 1 enroll in either study based on CST and BCVA Mild macular edema CST≥320 and <400 Moderate to severe macular edema CST ≥400 93 PEAK and PINNACLE – Key question: are these identical studies? PEAK Master Protocol Design A single screening process for both studies CST≥320 and BCVA 25-78 letters Mild to severe vision impairment BCVA 25-78 Moderate to severe vision impairment BCVA 25-70 Mild vision impairment BCVA 71-78 Based on the MESI patient population studied in APEX, two distinct and complementary sub-populations will be studied in PEAK and PINNACLE, allowing both studies to run concurrently in all study sites and covering a wide spectrum of MESI patients Moderate to severe edema with moderate to severe vision impairment Mild edema with any vision impairment Moderate to severe edema with good vision PINNACLE